ZyVersa治疗计划第2阶段,对Cholesterol Efflus调解员VAR 200进行H2 2024糖尿病肾病试验。 ZyVersa Therapeutics plans Phase 2a trial of Cholesterol Efflux Mediator VAR 200 for diabetic kidney disease in H2 2024.
临床阶段生物制药公司ZyVersa Therapeutics预计,对糖尿病病的VAR 200胆固醇排泄媒介的第二期a期试验将于2024年下半年开始,第一名患者将很快被录取. ZyVersa Therapeutics, a clinical-stage biopharma firm, expects its Phase 2a trial for Cholesterol Efflux Mediator VAR 200 in diabetic kidney disease to begin in H2 2024, with the first patient enrolled soon. 该公司还将肥胖症及相关新陈代谢并发症作为主要指标,作为Inflammasome ASC Inhibitor IC 100的主要指标,计划在Q4 2024年提交IND文件,然后在Q1 2025年进行第一阶段试验。 The company also targets obesity with related metabolic complications as the lead indication for its Inflammasome ASC Inhibitor IC 100, with an IND submission planned in Q4 2024 followed by a Phase 1 trial in Q1 2025. 尽管Q2净损失280万美元,但ZyVersa在研发工作方面取得了进展,其0.1M现金储备预计将为业务供资。 Despite a Q2 net loss of $2.8M, ZyVersa made progress in R&D efforts, and its $0.1M cash reserves are expected to fund operations.